full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for August, 2014

28
Aug

Shares of OncoMed Pharmaceuticals took a nasty tumble a couple of months ago when it hit the brakes on a pair of early-stage programs for two of its treatments after investigators noted trouble with some bone-related adverse events. Today, the biotech says it adjusted its protocols on vantictumab, a Wnt pathway inhibitor program, to the […]

26
Aug

Novartis’ big generics operation at Sandoz has been one of the leaders in the field of biosimilar development. So when the chief lays out a timetable on the adoption of these long-awaited knockoffs of some of the industry’s biggest biologics, FierceBiotech listens. …read more Source: Novartis CEO predicts a looming biosimilars boom     

26
Aug

Civitas Therapeutics has nailed down a substantial $55 million venture round aimed at getting its lead program for Parkinson’s through Phase III and onto the market. The Chelsea, MA-based biotech is developing CVT-301, a fast-acting rescue formulation of levodopa that can be self-administered through an inhaler. …read more Source: Civitas nails $55M venture round for […]

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off